Compare · GLP-1 agonist
Amycretin vs Liraglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Liraglutide | |
|---|---|---|
| Evidence | 6/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an experimental drug from Novo Nordisk. Its early weight-loss numbers have turned heads, which is exactly why it keeps popping up on peptide forums and gray-market menus. It is a single molecule (one compound, not a blend) that switches on two receptors at the same time — the GLP-1…
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…